荧光显像剂在甲状腺髓样癌原位模型中的生物学评价
本研究对经IRdye800标记的Compound-17进行生物学表征,用于甲状腺髓样癌(MTC)小鼠模型的荧光可视化。体外及体内实验中该化合物对两种人MTC细胞系(TT和MZ-CRC1)具有高亲和力,并在新建立的MTC原位异种移植模型中产生荧光信号,与序列打乱的对照化合物及周围正常组织相比具有区分度。结论认为Compound-17是识别MTC的独特有效分子,可能具有治疗潜力。
要点
- Compound-17经IRdye800标记后可在MTC小鼠模型中实现荧光可视化。
- 该化合物在体外和体内对TT和MZ-CRC1两种人MTC细胞系具有高亲和力。
- 在新建立的MTC原位异种移植模型中,Compound-17产生荧光信号,与序列打乱的对照化合物及周围正常组织相比具有区分度。
核心结论
- Compound-17是识别MTC的独特有效分子,可能具有治疗潜力。
研究设计与样本
- 对经IRdye800标记的Compound-17进行生物学表征,并在MTC小鼠模型中进行荧光可视化评价。
- 体外和体内实验使用两种人MTC细胞系TT和MZ-CRC1评估化合物亲和力。
- 在新建立的MTC原位异种移植模型中测试Compound-17的亲和力,并与序列打乱的对照化合物及周围正常组织进行比较。
主要发现
- Compound-17在体外和体内对TT和MZ-CRC1两种人MTC细胞系具有高亲和力。
- 在MTC原位异种移植模型中,Compound-17在MTC来源的原位异种移植瘤内产生荧光信号,与序列打乱的对照化合物及周围正常组织相比具有区分度。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The primary and definitive treatment of medullary thyroid cancer (MTC) is surgical resection. Recurrent or residual disease is typically a result of incomplete surgical removal. OBJECTIVE: Our objective is to develop a compound that assists in intraoperative visualization of cancer, which would have the potential to improve surgical cure rates and outcomes. RESULTS: We report the biological characterization of Compound-17, which is labeled with IRdye800, allowing fluorescent visualization of MTC mouse models. We found that the agent has high affinity for two human MTC cell lines (TT and MZ-CRC1) in vitro and in vivo. We further tested the affinity of the compound in a newly developed MTC orthotopic xenograft model and found that Compound-17 produces fluorescent signals within MTC-derived orthotopic xenografts in comparison with a sequence-jumbled control compound and surrounding normal tissues. CONCLUSIONS: Compound-17 is a unique and effective molecule for MTC identification that may have therapeutic potential.
引用
- Rossfeld KK, Justiniano SE, Ding H, et al. Biological Evaluation of a Fluorescent-Imaging Agent for Medullary Thyroid Cancer in an Orthotopic Model. J Clin Endocrinol Metab. 2017. PMID: 28591772. doi:10.1210/jc.2017-00573
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。